Job & career
Research & development
Formation of B·R·A·H·M·S Diagnostica GmbH.
First MBO of the German pharmaceuticals industry from the former Diagnostic Procedures business segment of Henning Berlin/Marion Merrell Dow.
Extension of the business activities to crucial research in the fields of thyroid diseases, auto-immune diseases, and life-threatening infections.
Product placement of PCT, the first test procedure for an early detection of sepsis.
Foundation of B·R·A·H·M·S France S.A.R.L. in Paris and other subsidiaries.
ISO 9001 – certified quality management.
Product placement of a quick sepsis test in the point-of-care format.
Product placement of TRAKhuman, by now the established procedure for the diagnosis of Graves disease.
Foundation of the Biotech Centre Hennigsdorf.
Takeover of the KRYPTOR laboratory system.
in Bagnols sur Cèze, France.
Transformation into a stock corporation.
Cezanne S.A.S. facilities destroyed as a result of a catastrophic flood in southern France
Company relocates to new premises in Nîmes
Focus on diagnostics business
Tenth anniversary celebration with ceremony at the Axica Forum on Berlin’s Pariser Platz
Additional benefit of PCT test in antibiotic therapies announced in The Lancet
Manual PCT test approved by FDA for use in the United States
New shareholder structure
New clinical developments for new cardiac biomarkers
Sales record of 50 million Euro reached in December
Foundation of BRAHMS UK Ltd in November
New Sales record of 60 million Euro reached in December
Foundation of BRAHMS Italia Srl. in February
FDA-Clearance of PCT Kryptor-test in USA
Foundation of BRAHMS Iberia S.L. in May
In September: B·R·A·H·M·S and Thermo Fischer Scientific join forces to create a leader in specialty diagnostics.
Competition Authorities approve Acquisition of B·R·A·H·M·S by Thermo Fisher Scientific
Transformation into a GmbH (private limited company) on May 27, 2010